AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.9 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Corrigenda | Open Access

Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis” [Genes & Diseases 11 (2024) 479–494]

Yanran Bia,b,1Ruiling Zhenga,1Jiahao Huc,1Ruiqing ShiaJunfeng ShiaYutao WangaPeng WangaWenyi JiangaGyudong Kimb( )Zhiguo Liua( )Xiaokun Lia( )Li Lina,d( )
School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China
College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 61186, Republic of Korea
Department of Dermatology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou 325000, China
Zhejiang Lab for Regenerative Medicine, Oujiang Laboratory, Wenzhou 325035, China

Peer review under responsibility of Chongqing Medical University.

1 These authors contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Genes & Diseases
Article number: 101168

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Bi Y, Zheng R, Hu J, et al. Corrigendum to “A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis” [Genes & Diseases 11 (2024) 479–494]. Genes & Diseases, 2024, 11(3): 101168. https://doi.org/10.1016/j.gendis.2023.101168

557

Views

7

Downloads

1

Crossref

1

Web of Science

0

Scopus

0

CSCD

Published: 15 November 2023
© 2023 The Authors.